Harold Fuller, MD
Psychiatry · Spartanburg, SCNPI 1376578252
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 44.9% of the total. Reporting peaked in 2019 at $330 and has fallen 86.1% since, to $46 in 2024.
Across 32 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$294
- Genentech USA, Inc.$122
- Takeda Pharmaceuticals U.S.A., Inc.$53
- Johnson & Johnson$44
- Lundbeck LLC$38
- AbbVie$29
- plus $76 from 4 others
What the payments were for
- Food & beverage$656100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 17 | $294 |
| Genentech USA, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Johnson & Johnson | 3 | $44 |
| Lundbeck LLC | 2 | $38 |
| AbbVie(2 entities) | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
How this compares
$656 in reported general payments places this provider in the 60th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 14 | $157 |
| Lamotrigine | 13 | $146 |
| Quetiapine Fumarate | 23 | $120 |
| Risperidone | 11 | $117 |
| Escitalopram Oxalate | 13 | $105 |
| Trazodone Hcl | 15 | $60 |
| Mirtazapine | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Spartanburg
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Nikunjkumar ModiFlorence$133K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.